International Journal of Hematology

, Volume 88, Issue 1, pp 82–87

JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera

  • Kentaro Yoshinaga
  • Naoki Mori
  • Yan-hua Wang
  • Kaori Tomita
  • Masayuki Shiseki
  • Toshiko Motoji
Original Article


A single mutation 1849G>T in the JAK2 gene (V617F) has recently been described in classical myeloproliferative disorders (MPD). To investigate the incidence and clinical significance of the JAK2 mutation, we performed allele-specific polymerase chain reaction (PCR) and enzyme-based assessment in 11 idiopathic erythrocytosis (IE) and 15 polycythemia vera (PV) patients. Aberrant bands indicating the V617F mutation were detected in only one of 11 patients with IE, whereas all of the 15 patients with PV showed the JAK2 mutation. Sequence analysis was subsequently performed in the IE patient showing aberrant bands on allele-specific PCR, and a nucleotide change corresponding to the V617F mutation was detected in four of 29 clones tested. This patient might have progressed to PV according to the new WHO diagnostic criteria proposed in 2007, since a gradual increase in platelet counts was observed 4 years after the time of diagnosis. A further longitudinal study monitoring V617F positive-cells will clarify the process of progression from IE to PV in such a patient.


JAK2 Idiopathic erythrocytosis Polycythemia vera 


  1. 1.
    Ihle JN, Gilliland DG. Jak2: normal function and role in hemotopoietic disorders. Curr Opin Genet Dev. 2007;17:8–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Baxter EJ, Scott LM, Cambell PJ, et al. Acquired mutation of tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMedGoogle Scholar
  3. 3.
    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloploliferative disorders. N Engl J Med. 2005;352:1779–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Cambell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polythaemia vera based JAK2 V617F muatation status: a prospective study. Lancet. 2005;366:1945–53.CrossRefGoogle Scholar
  5. 5.
    Levine RL, Wadleigh M, Cool J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.PubMedCrossRefGoogle Scholar
  7. 7.
    McMuillin MF, Bareford D, Cambell P, et al. Guidelines for diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174–95.CrossRefGoogle Scholar
  8. 8.
    Finazzi G, Gregg XT, Barbui T, et al. Idiopathic erythrocytosis and other non-clonal polycythemias. Best Pract Res Cl Hal. 2006;19:471–82.CrossRefGoogle Scholar
  9. 9.
    Blacklock HA, Royle GA. Idiopathic erythrocytosis—a declining entity. Br J Haematol. 2001;115:774–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Najean Y, Triebel F, Dresch C. Pure erythrocytosis: reappraisal of study of 51 cases. Am J Hematol. 1981;10:129–36.PubMedCrossRefGoogle Scholar
  11. 11.
    Michiels IJ, Barbui T, Finazzi G, et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma. 2000;36:239–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Murphy S, Petersen P, Iland H, et al. Experience of the Polycythemia Vera study group with essential thrombocythemia: a final report on diagnostic criteria, suvival and leukemic transition by treatment. Semin Hematol. 1997;34:29–39.PubMedGoogle Scholar
  13. 13.
    Pierre R, Imbert M, Thiele J, et al. Polycythaemia vera WHO classification of tumors, tumors of hematopietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 32–4.Google Scholar
  14. 14.
    Woodman RC, Reinhardt P, Kanwar S, et al. Effects of human neutrophil elastase (HNE) on neutrophil function function in vitro and in inflamed microvessels. Blood. 1993;82:2188–95.PubMedGoogle Scholar
  15. 15.
    Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythrmia vera and idiopathephic erythrocytosis. N Engl J Med. 2007;356:459–68.PubMedCrossRefGoogle Scholar
  16. 16.
    Percy MJ, Jones FGC, Green AR, et al. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Hematologica. 2006;91:413–4.Google Scholar
  17. 17.
    Rossi D, Cortini F, Deambrogi C, et al. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia. Leuk Res. 2007;31:97–101.PubMedCrossRefGoogle Scholar
  18. 18.
    Modan B, Modan M. Benign erythrocytosis. British J Haematol. 1968;14:375–81.CrossRefGoogle Scholar
  19. 19.
    Pearson TC, Wethereley MG. The course and complications of idiopathic erythrocytosis. Clin Lab Hematol. 1979;1:189–96.Google Scholar
  20. 20.
    Finazzi G, Ruggeri M, Marconi M, et al. The natural history of idiopathic erythrocytosis: a cohort study of 74 patients. Blood. 2004;104:421aGoogle Scholar
  21. 21.
    Williams DM, Kim AH, Rogers O, et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35:1641–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Kentaro Yoshinaga
    • 1
  • Naoki Mori
    • 1
  • Yan-hua Wang
    • 1
  • Kaori Tomita
    • 1
  • Masayuki Shiseki
    • 1
  • Toshiko Motoji
    • 1
  1. 1.Department of HematologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations